Welcome to our dedicated page for Icad news (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad stock.
This page provides a historical news archive for iCAD, Inc. (formerly NASDAQ: ICAD), a company that described itself as a global leader in clinically proven AI-powered breast health and cancer detection solutions. Before becoming a wholly owned subsidiary of RadNet, Inc., iCAD regularly issued news releases detailing its product developments, clinical research, commercial partnerships, and financial performance.
Readers can review announcements about the ProFound Breast Health Suite, which iCAD characterized as an industry-leading AI-powered mammography analysis platform for breast cancer detection, density assessment, and risk evaluation. News items include updates on FDA clearances for ProFound Detection versions, the introduction of ProFound Cloud as a scalable SaaS platform, and collaborations that integrated iCAD’s AI technology into radiology information systems, PACS platforms, and cloud-based precision imaging networks.
The archive also covers financial news, such as quarterly and annual results, trends in annual recurring revenue associated with the company’s transition to a subscription and cloud-based model, and commentary from management on operating performance. Additional releases highlight clinical abstracts and presentations at major conferences, where research collaborators evaluated iCAD’s AI tools for early detection, risk prediction, and breast arterial calcification assessment across diverse populations.
Because iCAD completed a merger with RadNet in July 2025 and its common stock ceased trading independently, the ICAD news feed now serves as a record of historical communications from iCAD’s time as a standalone public company. Investors, clinicians, and researchers can use this archive to understand how the company described its technology, strategy, and clinical evidence prior to its integration into RadNet’s diagnostic imaging and digital health portfolio.
iCAD Inc (NASDAQ: ICAD), a leader in AI-powered cancer detection solutions, has announced its plan to release Q2 2024 financial results on August 13, 2024, after market close. The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss the results. Investors and analysts can access the call via toll-free number 888-506-0062 (US) or 973-528-0011 (International) using the participant access code 227167. A webcast of the earnings call will also be available for those who prefer to listen online.
iCAD (NASDAQ: ICAD) has announced a strategic agreement with Windsong Radiology Group, part of US Radiology Specialists, to implement iCAD's ProFound AI Breast Health Suite at Windsong Radiology centers. This AI-powered technology aims to improve mammography readings' accuracy and efficiency, potentially reducing false positives and unnecessary biopsies.
The collaboration aligns with iCAD's mission to enhance early cancer detection and provide broader access to AI capabilities in mammography. Windsong Radiology, as a leader in women's imaging, views this adoption as a step towards clinical excellence and innovation in patient care. US Radiology Specialists, with over 175 outpatient imaging centers across 13 states, sees this integration as a significant advancement in offering high-quality imaging services.
iCAD announced new research showcasing the ProFound AI Risk algorithm’s efficacy in breast cancer risk prediction. Presented at the Society for Imaging Informatics in Medicine (SIIM) Annual Meeting, the study highlights the AI's ability to identify high-risk individuals by analyzing changes in mammographic features. The research suggests a two-fold increase in risk for every 0.2 unit increase in the AI-derived score.
Additionally, iCAD introduced ProFound Cloud, a SaaS platform built on Google Cloud. This platform provides scalable, secure, and cost-effective access to the company's breast health AI solutions, enhancing diagnostic accuracy and operational efficiency. Preliminary data shows it processes cases 50% faster than traditional methods. Healthcare providers can integrate these solutions to improve patient outcomes while reducing infrastructure costs.
iCAD, a leader in AI-powered breast health solutions, will present at the MedInvest MedTech, AI & Digital Healthcare Conference in San Francisco on June 11-12, 2024. CEO Dana Brown and CFO Eric Lonnqvist will participate in one-on-one meetings with investors. This event underscores iCAD's commitment to leveraging AI in cancer detection and its ongoing engagement with the investment community.
iCAD (NASDAQ: ICAD) reported its financial results for Q1 2024, showing notable improvements across several metrics. Total revenue increased by 14% year-over-year to $5.0 million. Gross profit margin rose to 83% from 82%, contributing to a gross profit of $4.1 million. Despite a GAAP net loss of $1.2 million, this marks a significant improvement from the $3.1 million loss in Q1 2023. Operating expenses decreased by 18% to $5.6 million. The company's ARR also grew by 10% to $9.0 million. Cash and cash equivalents stood at $20.3 million as of March 31, 2024.
iCAD, Inc. (NASDAQ: ICAD) will report its financial results for the first quarter of 2024 on May 15, 2024, and host a conference call at 8:30 AM Eastern Time. The company specializes in AI-powered cancer detection solutions.
iCAD, Inc. will report its first quarter financial results on May 15, 2024. The company specializes in AI-powered cancer detection solutions. The earnings call will provide insights into the company's performance for the quarter ended March 31, 2024.
Summary not available.
Summary not available.
Summary not available.